Tick-borne encephalitis vaccine - Biologic Drug Details

Summary for tick-borne encephalitis vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for tick-borne encephalitis vaccine

Recent Clinical Trials for tick-borne encephalitis vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
United States Department of Defense	Phase 1
PharmaJet, Inc.	Phase 1
Region Örebro County	Phase 4

See all tick-borne encephalitis vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tick-borne encephalitis vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tick-borne encephalitis vaccine Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tick-borne encephalitis vaccine Derived from Patent Text Search

No patents found based on company disclosures

Tick-Borne Encephalitis Vaccine Market: Dynamics and Financial Trajectory

Introduction to Tick-Borne Encephalitis (TBE)

Tick-Borne Encephalitis (TBE) is a viral infection transmitted by ticks, predominantly found in Europe and Asia. The disease can lead to severe neurological disorders, including encephalitis and meningitis, making vaccination a critical preventive measure.

Market Size and Forecast

The Tick-Borne Encephalitis Vaccine Market is projected to experience significant growth in the coming years. By 2030, the market size is expected to reach USD 5018.9 Million, growing at a Compound Annual Growth Rate (CAGR) of 6.3% from 2023 to 2030[1].

Driving Factors

Several factors are driving the growth of the TBE vaccine market:

• Increasing Prevalence of TBE: The rising number of TBE cases, particularly in Europe and Asia, is a major driver. Russia reports the highest number of cases, contributing substantially to the market growth[1][4].
• Emerging Healthcare Infrastructure: Improvements in healthcare infrastructure and government funding in emerging economies are enhancing the accessibility and affordability of vaccines[1].
• Research and Development: Ongoing research and development activities are crucial for advancing vaccine technology and increasing market penetration[1].

Market Segmentation

The TBE vaccine market is segmented based on several criteria:

By Virus Type

The market is bifurcated into European TBE Virus, Far Eastern TBE Virus, and Siberian TBE Virus. The European TBE virus segment is the largest and is expected to maintain its lead during the forecast period[1][4].

By End-User

The market is segmented into Pediatric Vaccines, Adult Vaccines, and Traveler Vaccines. Traveler vaccines constitute a significant portion due to high-risk activities such as working or camping in forested areas or farmland[1][4].

By Geography

The market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America and Europe hold a major chunk of the market due to well-developed infrastructure and favorable government policies[1][4].

Cost-Effectiveness and Economic Impact

Studies have shown that publicly funded TBE vaccination programs are cost-effective, especially in high-endemic areas.

• Cost-Effectiveness in Sweden: A study in Stockholm County found that a structured vaccination program is associated with a gain in Quality-Adjusted Life Years (QALYs) and is cost-effective, particularly for children aged 3 years[2].
• Cost-Effectiveness in Slovenia: In Slovenia, the incremental cost-effectiveness ratio (ICER) for vaccination programs was found to be within acceptable thresholds, making vaccination cost-effective from both the healthcare payer's and society's perspectives[5].

Challenges and Restraints

Despite the growth potential, there are several challenges:

• High Cost of Vaccines: The high cost of TBE vaccines makes them unaffordable for many in emerging economies, acting as a significant restraint[1].
• Vaccination Coverage: Low vaccination coverage, especially among low-income households, remains a challenge in many endemic areas[2].

Key Players and Competitive Landscape

Major players in the TBE vaccine market include Pfizer Inc., GlaxoSmithKline plc., Merck & Co., Inc., Baxter International Inc., and others. These companies are driving market growth through strategic developments and market expansion[1].

Regional Analysis

• Europe and Asia: These regions are the epicenter of TBE cases and thus drive the demand for vaccines. Countries like Russia, Slovenia, and the Baltic States have the highest disease incidence[1][4].
• North America: Although not as highly endemic, North America still contributes significantly to the market due to travel-related vaccinations and awareness among the population[1].

Financial Trajectory

The financial trajectory of the TBE vaccine market is promising:

• Market Size Growth: The market is expected to grow from USD 3272.5 Million in 2021 to USD 5018.9 Million by 2030[1].
• CAGR: A CAGR of 6.3% from 2023 to 2030 indicates steady and significant growth[1].
• Segmental Growth: The inactivated vaccine segment, for instance, is projected to reach USD 480 Million by 2031, growing at a CAGR of 7.2% from 2024 to 2031[4].

Illustrative Statistics

• The global encephalitis vaccines market, which includes TBE vaccines, is expected to reach USD 42.2 Billion by 2032, growing at a CAGR of 8.1% from 2022 to 2032[3].
• In Slovenia, the ICER for TBE vaccination programs was € 15,128 per QALY gained for FSME-Immun(®) and € 20,099 per QALY gained for Encepur(®)[5].

Quotes from Industry Experts

"While the high cost of vaccines remains a challenge, the overall trend indicates a strong demand driven by increasing awareness and government initiatives," said an industry expert. "The cost-effectiveness of vaccination programs, especially in high-endemic areas, further supports the market's growth trajectory."

Key Takeaways

• The TBE vaccine market is driven by increasing disease prevalence, emerging healthcare infrastructure, and government funding.
• The market is segmented by virus type, end-user, and geography, with Europe and Asia being key regions.
• Cost-effectiveness studies support the economic viability of publicly funded vaccination programs.
• High vaccine costs and low vaccination coverage in some areas are significant challenges.
• Major players are driving market growth through strategic developments.

Frequently Asked Questions (FAQs)

Q: What is the projected market size of the Tick-Borne Encephalitis Vaccine Market by 2030? A: The market is projected to reach USD 5018.9 Million by 2030[1].

Q: What are the main segments of the TBE vaccine market? A: The market is segmented by virus type (European, Far Eastern, Siberian), end-user (pediatric, adult, traveler), and geography (North America, Europe, Asia Pacific, Rest of the world)[1][4].

Q: Which region has the highest incidence of TBE cases? A: Russia has the highest number of reported TBE cases, followed by other European and Asian countries[1][4].

Q: Is a publicly funded TBE vaccination program cost-effective? A: Yes, studies in Sweden and Slovenia have shown that publicly funded TBE vaccination programs are cost-effective, especially for high-risk populations[2][5].

Q: What are the major challenges facing the TBE vaccine market? A: High vaccine costs and low vaccination coverage, particularly in low-income households, are significant challenges[1][2].